Literature DB >> 21785870

Specific expression of ZO-1 and N-cadherin in rosette structures of various tumors: possible recapitulation of neural tube formation in embryogenesis and utility as a potentially novel immunohistochemical marker of rosette formation in pulmonary neuroendocrine tumors.

Kaishi Satomi1, Yukio Morishita, Shingo Sakashita, Yuzuru Kondou, Shuichiroh Furuya, Yuko Minami, Masayuki Noguchi.   

Abstract

Neuroendocrine tumors can develop in various organs. All of these tumors are designated on the basis of their morphologic characteristics evident by light microscopy, and by immunohistochemistry for antigens such as synaptophysin, chromogranin-A, and CD56/NCAM. In the present study, we attempted to demonstrate the localization of Zonula occludens-1 (ZO-1) and N-cadherin in rosette structures of neuroendocrine tumors using immunohistochemistry and to clarify their specific distribution in rosettes in human pulmonary neuroendocrine tumors in comparison with various types of adenocarcinoma. Among 40 neuroendocrine tumors of the lung examined, 18 cases (45%) and 22 cases (55%) were positive for ZO-1 and N-cadherin, respectively. In addition, we divided the cases into two types: 16 cases of Flexner-type tumor and 24 cases of Homer-Wright-type tumor. We then determined the Rosette Index (RoI; the percentage fraction of rosette structures positive for ZO-1 or N-cadherin among the total number of rosette structures). The Flexner-type neuroendocrine tumors showed significantly higher levels of RoI in ZO-1 than the Homer-Wright-type neuroendocrine tumors (median; 38.8% vs 0%, p < 0.001). On the other hand, N-cadherin and ZO-1 were hardly detected in tubular adenocarcinomas in various organs, and their immunoreactivities differed significantly between adenocarcinoma and pulmonary neuroendocrine tumor (ZO-1, mean 0.23% vs 18%, p < 0.0001; N-cadherin, mean 0% vs 33%, p < 0.0001). In conclusion, expression of ZO-1 and N-cadherin may reflect the mechanisms leading to rosette formation in neuroendocrine tumors, which possibly recapitulate neural tube formation in embryogenesis and could represent a specific immunohistochemical marker for neuroendocrine carcinoma of the lung.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21785870     DOI: 10.1007/s00428-011-1120-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  29 in total

Review 1.  Neuropathology for the neuroradiologist: rosettes and pseudorosettes.

Authors:  F J Wippold; A Perry
Journal:  AJNR Am J Neuroradiol       Date:  2006-03       Impact factor: 3.825

2.  Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases.

Authors:  A Carretta; G L Ceresoli; G Arrigoni; B Canneto; M Reni; C Cigala; P Zannini
Journal:  Lung Cancer       Date:  2000-09       Impact factor: 5.705

3.  Behaviour and survival of high-grade neuroendocrine carcinomas of the lung.

Authors:  J M Naranjo Gómez; J J Gómez Román
Journal:  Respir Med       Date:  2010-12       Impact factor: 3.415

4.  ZO-1 determines adherens and gap junction localization at intercalated disks.

Authors:  Joseph A Palatinus; Michael P O'Quinn; Ralph J Barker; Brett S Harris; Jane Jourdan; Robert G Gourdie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-03       Impact factor: 4.733

5.  Neuroendocrine neoplasms of the bronchopulmonary tract. A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants.

Authors:  W H Warren; V E Gould; L P Faber; C F Kittle; V A Memoli
Journal:  J Thorac Cardiovasc Surg       Date:  1985-06       Impact factor: 5.209

Review 6.  Neuroendocrine neoplasms of the lung. A clinicopathologic update.

Authors:  W H Warren; L P Faber; V E Gould
Journal:  J Thorac Cardiovasc Surg       Date:  1989-09       Impact factor: 5.209

7.  Deficiency of zonula occludens-1 causes embryonic lethal phenotype associated with defected yolk sac angiogenesis and apoptosis of embryonic cells.

Authors:  Tatsuya Katsuno; Kazuaki Umeda; Takeshi Matsui; Masaki Hata; Atsushi Tamura; Masahiko Itoh; Kosei Takeuchi; Toshihiko Fujimori; Yo-ichi Nabeshima; Tetsuo Noda; Shoichiro Tsukita; Sachiko Tsukita
Journal:  Mol Biol Cell       Date:  2008-03-19       Impact factor: 4.138

8.  Expression of tight-junction-associated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival.

Authors:  Satoshi Ohtani; Masanori Terashima; Jun Satoh; Nobutoshi Soeta; Zenichiroh Saze; Seigo Kashimura; Fumihiko Ohsuka; Yutaka Hoshino; Michihiko Kogure; Mitsukazu Gotoh
Journal:  Gastric Cancer       Date:  2009-04-24       Impact factor: 7.370

9.  The 220-kD protein colocalizing with cadherins in non-epithelial cells is identical to ZO-1, a tight junction-associated protein in epithelial cells: cDNA cloning and immunoelectron microscopy.

Authors:  M Itoh; A Nagafuchi; S Yonemura; T Kitani-Yasuda; S Tsukita; S Tsukita
Journal:  J Cell Biol       Date:  1993-05       Impact factor: 10.539

10.  Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia.

Authors:  B R Stevenson; J D Siliciano; M S Mooseker; D A Goodenough
Journal:  J Cell Biol       Date:  1986-09       Impact factor: 10.539

View more
  2 in total

1.  Why does melanoma metastasize into the brain? Genes with pleiotropic effects might be the key.

Authors:  Anatoliy I Yashin; Deqing Wu; Konstantin G Arbeev; Alexander M Kulminski; Eric Stallard; Svetlana V Ukraintseva
Journal:  Front Genet       Date:  2013-05-01       Impact factor: 4.599

2.  Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors.

Authors:  Jose A Galván; Aurora Astudillo; Aitana Vallina; Guillermo Crespo; Maria Victoria Folgueras; Maria Victoria González
Journal:  BMC Cancer       Date:  2014-11-20       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.